Analyzing the Sensitivity of EGFR-L861Q Mutation to TKIs and A Case Report

Analyzing the Sensitivity of EGFR-L861Q Mutation to TKIs and A Case Report

Background and objective The significant efficacy of tyrosine kinase inhibitors (TKIs) has been approved for advanced non-small cell lung cancer (NSCLC) patients with activating epidermal growth factor receptor (EGFR) mutations. No clear evidence exists that EGFR-L861Q is sensitive to TKIs, and the...

Full description

Bibliographic Details
Main Authors: Xingxing WANG, Yutong DONG, Tingting LIANG, Xiongji ZHANG, Kewei MA, Yongsheng CUI
Format: Article
Language:zho
Published: Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2015-09-01
Series:Chinese Journal of Lung Cancer
Subjects:
Lung neoplasms
EGFR-L861Q mutation
Protein conformation
Tyrosine kinase inhibitors
Online Access:http://dx.doi.org/10.3779/j.issn.1009-3419.2015.09.11

Internet

http://dx.doi.org/10.3779/j.issn.1009-3419.2015.09.11

Similar Items